Zobrazeno 1 - 10 of 92 pro vyhledávání: '"Hana, Klamova"'
1
Akademický článek
Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
Autor: Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Ivana Jeziskova, Katerina Machova Polakova, Pavel Zak, Tereza Jurkova, Marika Chrapava, Jiri Mayer
Publikováno v: Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world clinical practice. Methods A propensity score analysis was performed to elim
Externí odkaz: https://doaj.org/article/a3f1e095df1743329fc066dd5daac827
Zobrazit plný text záznamu
2
Akademický článek
Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining
Autor: Nikola Curik, Vaclava Polivkova, Pavel Burda, Jitka Koblihova, Adam Laznicka, Tomas Kalina, Veronika Kanderova, Jana Brezinova, Sarka Ransdorfova, Dominika Karasova, Katerina Rejlova, Marina Bakardjieva, Daniela Kuzilkova, David Kundrat, Jana Linhartova, Hana Klamova, Cyril Salek, Pavel Klener, Ondrej Hrusak, Katerina Machova Polakova
Publikováno v: Frontiers in Oncology, Vol 11 (2021)
Somatic mutations are a common molecular mechanism through which chronic myeloid leukemia (CML) cells acquire resistance to tyrosine kinase inhibitors (TKIs) therapy. While most of the mutations in the kinase domain of BCR-ABL1 can be successfully ma
Externí odkaz: https://doaj.org/article/8005ecfc126d4bfeaf825124b03f64ae
Zobrazit plný text záznamu
3
Akademický článek
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
Autor: Monika Jaruskova, Nikola Curik, Rajna Hercog, Vaclava Polivkova, Eliska Motlova, Vladimir Benes, Hana Klamova, Pavla Pecherkova, Petra Belohlavkova, Filip Vrbacky, Katerina Machova Polakova
Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-17 (2017)
Abstract Background Through high-throughput next-generation sequencing of promoters of solute carrier and ATP-binding cassette genes, which encode drug transporters, we aimed to identify SNPs associated with the response to imatinib administered for
Externí odkaz: https://doaj.org/article/50d802bfd6834c5e9b0ebd9a761a70af
Zobrazit plný text záznamu
4
Akademický článek
BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
Autor: Klara Srutova, Nikola Curik, Pavel Burda, Filipp Savvulidi, Giovannino Silvestri, Rossana Trotta, Hana Klamova, Pavla Pecherkova, Zofie Sovova, Jitka Koblihova, Tomas Stopka, Danilo Perrotti, Katerina Machova Polakova
Publikováno v: Haematologica, Vol 103, Iss 12 (2018)
The fusion oncoprotein BCR-ABL1 exhibits aberrant tyrosine kinase activity and it has been proposed that it deregulates signaling networks involving both transcription factors and non-coding microRNAs that result in chronic myeloid leukemia (CML). Pr
Externí odkaz: https://doaj.org/article/5a120df0b57040db90b998afc262735e
Zobrazit plný text záznamu
6
Akademický článek
AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome.
Autor: Jitka Koblihova, Klara Srutova, Monika Krutska, Hana Klamova, Katerina Machova Polakova
Publikováno v: PLoS ONE, Vol 13, Iss 11, p e0206620 (2018)
The increasing interest in exploring the human genome and identifying genetic risk factors contributing to the susceptibility to and outcome of diseases has supported the rapid development of genome-wide techniques. However, the large amount of obtai
Externí odkaz: https://doaj.org/article/683d04a4c0e34da88c1107ee745ea166
Zobrazit plný text záznamu
9
Akademický článek
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.
Autor: Vaclava Polivkova, Peter Rohon, Hana Klamova, Olga Cerna, Martina Divoka, Nikola Curik, Jan Zach, Martin Novak, Iuri Marinov, Simona Soverini, Edgar Faber, Katerina Machova Polakova
Publikováno v: PLoS ONE, Vol 11, Iss 5, p e0155959 (2016)
Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML) harboring the T315I mutation and compound or polyclonal mutations. However, in some individual case
Externí odkaz: https://doaj.org/article/eec7181a37d04b6a995c86b77927b702
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje